Investment Thesis
Replimune is a pre-revenue clinical-stage biotech with -$319.9M operating loss and -$280.3M annual cash burn, leaving only ~9 months of runway despite a $209M cash position. The company has zero commercial revenue and is entirely dependent on uncertain clinical trial outcomes, with no clear path to profitability in the near term based on current financial fundamentals.
Strengths
- Strong cash position of $209.0M provides operational runway for planned studies
- Excellent liquidity with 4.79x current ratio indicating ability to meet short-term obligations
- Conservative leverage at 0.50x debt-to-equity ratio with manageable debt service
Risks
- Zero revenue with no commercial-stage products generating sales
- Unsustainable burn rate of $280.3M annually leaves only ~9 months of cash runway
- Complete financial dependence on uncertain clinical trial outcomes and FDA approval - binary risk
- High likelihood of dilutive capital raise required before reaching profitability or positive cash flow
- Negative ROE (-188.9%) and ROA (-94.4%) reflect severe operational losses
Key Metrics to Watch
- Cash runway and burn rate trajectory - critical for assessing capital raise timing
- Clinical trial progress and milestone achievements
- Quarterly cash burn trend - any improvement would extend runway
Financial Metrics
Revenue
0.0
Net Income
-313.9M
EPS (Diluted)
$-3.38
Free Cash Flow
-284.6M
Total Assets
332.4M
Cash
209.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-188.9%
ROA
-94.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
4.79x
Quick Ratio
4.79x
Debt/Equity
0.50x
Debt/Assets
50.0%
Interest Coverage
-47.07x
Long-term Debt
83.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-07-29T06:02:06.574653 |
Data as of: 2026-03-31 |
Powered by Claude AI